Paris, 2011 the 29th of march - French pathogens discovery biotechnology start–up, PathoQuest SAS, raises 2M€ with Kurma BioFund in its first round of financing -Founded in September 2010 by Professor Marc Eloit and Luc Boblet (PhD), PathoQuest SAS completed, on March 11th 2011, its first round of financing securing 2 M€ with the Kurma BioFund. A spin-off from the Pasteur Institute and the Ecole Nationale Vétérinaire d’Alfort (ENVA), PathoQuest has developed a proprietary expertise in metagenomics and pathogens identification by “Binning” or “De novo assembling” of high-throughput generated sequences.
By discovering the etiology of major pathologies, in the field of infectious diseases and oncology, PathoQuest is committed to providing valuable new targets for diagnosis and vaccines to majors companies...
[...]
...About PathoQuest
A spin-off from the Pasteur Institute and l’Ecole Nationale Vétérinaire d’Alfort (ENVA), PathoQuest is a biotechnology start-up company dedicated to identifying pathogens by means of High Throughput Sequencing (HTS). PathoQuests’ extensive range of R&D programs in the fields of infectious diseases and oncology - both in-house and in collaboration with academic/industrial partners, permits PathoQuest to discover the etiology of major pathologies. PathoQuest is committed to providing diagnosis and vaccine pharmaceutical companies with valuable new targets. PathoQuest ultimately aims to be a pioneer in HTS-based medical diagnosis.
About Kurma Life Sciences Partners
Kurma Biofund is a venture capital fund managed by Paris based Kurma Life Sciences Partners (KLS Partners). Founded in July 2009, Kurma manages in excess of 135M€. KLS Partners is supported by two long-term investors (Natixis, part of Group BPCE the second largest French bank, and stateowned Caisse des Dépots et Consignations – CDC). Kurma actively invests in all stages of the biotech value chain, from technology transfer through to more established companies... [PDF] PathoQuest's Press Release - PDF du communiqué de presse de Kurma bioFund -
